BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23614702)

  • 21. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
    Schmiemann V; Böcking A; Kazimirek M; Onofre AS; Gabbert HE; Kappes R; Gerharz CD; Grote HJ
    Clin Cancer Res; 2005 Nov; 11(21):7728-34. PubMed ID: 16278393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum.
    Gilliland FD; Harms HJ; Crowell RE; Li YF; Willink R; Belinsky SA
    Cancer Res; 2002 Apr; 62(8):2248-52. PubMed ID: 11956078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study.
    Cirincione R; Lintas C; Conte D; Mariani L; Roz L; Vignola AM; Pastorino U; Sozzi G
    Int J Cancer; 2006 Mar; 118(5):1248-53. PubMed ID: 16152615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
    Takada S; Morita K; Hayashi K; Matsushima T; Sawamura M; Murakami H; Nojima Y
    Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance.
    Lee SM; Lee WK; Kim DS; Park JY
    Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
    Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [DNA methylation and telomere damage in occupational people exposed to coal tar pitch].
    Wang Y; Duan X; Zhang Y; Wang S; Yao W; Wang S; Wang W; Wu Y
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Jul; 33(7):507-11. PubMed ID: 26653646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
    Hasegawa M; Nelson HH; Peters E; Ringstrom E; Posner M; Kelsey KT
    Oncogene; 2002 Jun; 21(27):4231-6. PubMed ID: 12082610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
    Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
    Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: relation with smoking status.
    Yanagawa N; Tamura G; Oizumi H; Endoh M; Sadahiro M; Motoyama T
    Anticancer Res; 2011 Apr; 31(4):1211-4. PubMed ID: 21508367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aberrant promoter methylation as biomarker for molecular cytological diagnosis of lung cancer].
    Grote HJ
    Verh Dtsch Ges Pathol; 2006; 90():216-26. PubMed ID: 17867600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
    Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
    Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
    Cantor JP; Iliopoulos D; Rao AS; Druck T; Semba S; Han SY; McCorkell KA; Lakshman TV; Collins JE; Wachsberger P; Friedberg JS; Huebner K
    Int J Cancer; 2007 Jan; 120(1):24-31. PubMed ID: 17019711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.